Fibromuscular dysplasia, often abbreviated as FMD, is a non-atherosclerotic, non-inflammatory vascular disease that causes abnormal growth within the wall of an artery. FMD has been found in nearly every arterial bed in the body. However, the most common arteries affected are the renal and carotid arteries.
There are various types of FMD, with medial fibroplasia being the most common. Intimal and adventitial are less common forms of the disease. FMD predominantly affects middle-aged women, but has been found in men and people of all ages. Pediatric cases of FMD are vastly different from that of the adult population. The prevalence of FMD is not known. Although the disease was initially thought to be rare, recent studies have suggested that FMD may be under diagnosed .
- 1 Etiology/Pathophysiology
- 2 Presentation
- 3 Diagnosis
- 4 Treatment
- 5 Prognosis
- 6 Pediatrics
- 7 Related Diseases
- 8 References
- 9 External links
While the etiology of FMD remains unclear, current theory suggest that there may be a genetic predisposition as case reports have identified clusters of the disease and prevalence among twins . In fact, according to the Cleveland Clinic approximately 10% of cases appear to be inherited and often coexists with other genetic abnormalities that affect the blood vessels. Approximately 10% of patients with FMD have an affected family member. A study conducted from the patient registry at Michigan Cardiovascular Outcomes Research and Reporting Program (MCORRP) at the University of Michigan Health System reported a high prevalence of a family history of stroke (53.5%), aneurysm (23.5%), and sudden death (19.8%). Even though FMD is a non-atherosclerotic disease family histories of hypertension and hyperlipidemia were also common among those diagnosed with FMD. It is believed that the etiology of FMD is not a single identifier such as genetics but has multiple underlying factors. Theories of hormonal influence, mechanical stress from trauma and stress to the artery walls, and also the effect of loss of oxygen supply to the blood vessel wall caused by fibrous lesions . It has been suggested that environmental factors, such as smoking and estrogen, may play role in addition to genetic factors. These questions are making the discovery of FMD etiology prove to be difficult. Understanding the etiology and pathophysiology of FMD continues to be an area of active research through patient registries and the Fibromuscular Dysplasia Society of America (FMDSA).
FMD can be found in almost every artery in the human body, but most often affects the carotid, vertebral, renal arteries and even those that supply the intestines, arms, and the legs. Patients may present with FMD in multiple vessels. FMD has been pathologically categorized into three types of classifications: Medial, intimal, and adventitial; referring to the particular layer of arterial wall being affected.
In pediatrics the most prevalent form of FMD is intimal fibroplasia. Intimal fibroplasia is described as long, irregular or smooth focal stenosis and can occur in any arterial bed. Whilst it is the most common type amongst children, it only accounts for approximately 10% of FMD cases overall . It most often presents with ischemic symptoms, and frequently mistaken for Takayasu arteries .
The second type, medial fibroplasia, involves thickening of the media and collagen formation. It is typically reported as having the appearance of a ‘string of beads’ on angiographic review. "The 'bead' component is often larger than the normal arterial lumen, and in a subset of patients with FMD, aneurysms are present that may require treatment."  The medial subtype of FMD accounts for nearly 80% to 90% of all FMD cases.
The third classification is adventitial fibroplasia where collagen replaces the fibrous adventitia and extends beyond the artery. This form is considered rare but angiographic appearance may look similar to the intimal subtype of FMD making the distinction difficult.
Signs and symptoms that FMD patients present with is largely dependent on the vascular bed(s) affected. Patients may also be entirely asymptomatic and have FMD discovered incidentally, i.e. when imaging studies are performed for other reasons. In a study from the US Fibromuscular Dysplasia registry, the mean age at first symptom or sign was roughly 47 years of age.
The main symptoms associated with renal FMD are hypertension and bruits audible over the abdomen or flanks. Complications such as aneurysms, dissections, or occlusion of the renal artery have been associated with renal artery FMD.
The carotid and vertebral arteries are most commonly affected. Middle and distal regions of the internal carotid arteries are frequently involved. Patients with FMD in the carotid arteries typically present around 50 years of age. Symptoms of craniocervical involvement include headaches (mostly migraine), pulsatile tinnitus, dizziness, and neck pain, although patients are often asymptomatic. On physical examination, one may detect neurological symptoms secondary to a stroke or transient ischemic attack (TIA), a bruit over an affected artery, and diminished distal pulses. Complications of cerebrovascular FMD include TIA, ischemic stroke, Horner’s syndrome, or subarachnoid hemorrhage.
Patients with mesenteric, or intestinal FMD, may experience abdominal pain after eating or weight loss. FMD within the extremities may cause claudication or may be detectable by bruits. If the lower limb arteries are affected, the patient may present with cold legs or evidence of distal embolic disease. FMD present in the subclavian artery may cause arm weakness, parenthesis, claudication, and subclavial steal syndrome [9,10].
It is the lack of specific symptoms and its potential to appear anywhere that makes FMD a challenge to detect early on. In fact, it is essential that practitioner’s work collaboratively and interdisciplinary to combine clinical presentation and angiographic imaging to make the most accurate diagnosis. The FMD patient registry has uncovered startling evidence related to diagnostic timelines. According to the Michigan Outcomes Research and Reporting Program (MCORRP, 2013) the length of time from a patient’s first signs or symptoms to diagnosis is commonly 5 years. Reducing this diagnostic delay is paramount to early intervention and researchers are feverishly working to develop clinics specializing in FMD and to disseminate new knowledge to improve detection rates.
FMD is currently diagnosed through the use of both invasive and non-invasive tests. Non-invasive testing includes duplex ultrasonography, magnetic resonance angiography (MRA), and computed tomographic angiography (CTA). Invasive testing through angiography is the gold standard. However, due to the higher risk of complications this is often is not done early on. Occasionally, FMD is diagnosed asymptomatically after an unrelated x-ray presents the classic ‘string of beads’ appearance of the arteries, or when a practitioner investigates an unexpected bruit found during an exam. When a patient is considered for a diagnosis of FMD a thorough medical history, family history and vascular examination should be completed. It is important that a definitive diagnosis of FMD can only be made with imaging studies. Catheter-based angiography (with contrast) has proven to be the most accurate imaging technique, when a catheter is inserted into a large artery and advanced until it reaches the vessel of question. The catheter allows practitioners to view and measure the pressure of the artery aiding in the categorization and severity of the FMD diseased artery. According to Olin, “catheter-based angiography is the only imaging modality that can accurately identify the changes of FMD, aneurysm formation, and dissection in the branch vessels.” Practitioners believe it is important to utilize IVUS imaging because stenosis can sometimes only be detected through the methods of pressure gradient or IVUS imaging. In addition, computed tomography angiography and magnetic resonance angiography are commonly used to evaluate arteries in the brain. Doppler ultrasound may be used in both the diagnosis and follow-up of FMD.
There is no known cure for FMD. However, treatment focuses on relieving symptoms associated with it. Medical management is the most common form of treatment. The best approach to medically managing these patients is constantly being reevaluated as more information is learned about the disease.
Blood pressure control is the primary concern when treating patients with renal FMD. In cases of renal stenosis and indications for intervention, percutaneous balloon angioplasty may be recommended. Many studies have assessed the success rate of percutaneous transluminal angioplasty (PTA) in these cases, and have found relief of hypertensive symptoms.[6,7,8] Duplex ultrasonography should be performed soon after this procedure to ensure adequate renal velocities.
Stents are have a restenosis rate of 10-20%, and may make surgical revascularization more difficult. Surgical revascularization may be necessary if aneurysms develop within the affected artery or if PTA does not resolve the issue.
Patients with carotid or vertebral FMD should be medically managed to reduce the risk of a stroke. Aspirin 81 mg is typically prescribed for patients with carotid FMD. Antiplatelets and anticoagulants may be used to reduce the risk of blood clot formation. If a TIA or stroke are to occur, percutaneous angioplasty and antiplatelet therapy may be necessary.
Treatment for FMD in other regions
Little information is known regarding the best treatment for FMD outside of the renal and extracranial regions. If claudication or limb ischemia is consequent to FMD in the extremities, angioplasty may be implemented. 
Prognosis and outcome research is scant. In some cases if not managed properly FMD-related aneurysms can occur causing bleeding into the brain, resulting in stroke, permanent nerve damage, or death. Shedding light in the importance of detection and seeking appropriate care in reference to outcomes. What we do know is patients with medial fibroplasia generally have a favorable prognosis. However, those who present with FMD in multiple vascular beds, or intimal disease involving multiple branches of the renal arteries may develop renal artery dissection or progressive renal impairment. Therefore having a more difficult and complex prognostic course.
Children with FMD often report various non-specific symptoms or present with hypertension during routine physical examinations. Symptoms are commonly associated with the artery being affected. Symptoms may include headaches, insomnia, fatigue and chest or abdominal pain. FMD affecting the arteries of the head neck are commonly recognized as a cause of childhood strokes . It is important to note, that detection may stem from a bruit being present over the affected vascular bed during a physical assessment. Yet, absence of a bruit does not rule out significant vascular disease .
In children, renovascular disease accounts for approximately 10% of all causes of secondary hypertension . Renal failure is a common presentation in infants and children but is uncommon in adults, although it is occasionally the presenting problem in adults with intimal disease. “The presentation in infants and children younger than 4 years is especially likely to resemble vacuities.”
The differentiating presentations are suggestive of FMD being a unique syndrome in respect to the pediatric population. Experienced FMD clinicians warn against relying in the “string of beads” angiography for a diagnosis. In fact, it is suggested that FMD may be both under and over-diagnosed in children with stroke .
Pediatric FMD medical and surgical treatments or interventions are available. Treatment is determined by factors such as age and disease location but routinely involve controlling hypertension, re-establishing vascular flow, clot prevention, and improving lifestyle such as diet, exercise and smoking cessation .
Medical therapy for Pediatric population may involve the use of angiotensin-converting enzyme inhibitor (ACE inhibitors) and/or angiotensin II receptor blockers, multiple anti-hypertensive medications, diuretics, calcium channel blockers, and beta-blockers. Prevention of thrombosis of affected arteries may be taken through administration of an antiplatelet medication such as Aspirin . Percutaneous transluminal renal angioplasty (PTRA) remains the gold standard for renal-artery FMD. This treatment is useful when hypertension is difficult to control; patient is intolerant to the anti-hypertensive medications, non-complainant to medication regime and patient loss of renal volume due to ischemia . PTRA can also aide in preventing a lifelong dependency on a medication for such a young patient . According to Meyers, “effective PTRAs result in cured or controlled blood pressure, which is often signified by reductions in plasma rennin activity and angiotensin II levels, and when compared with surgery, percutaneous balloon angioplasty is less costly, able to be performed on an outpatient basis, results in lower morbidity, and the use of stenting is not primarily necessary.” However, there is a subset of the pediatric population that are resistant to PTRA . Adverse events may include, “recurrent stenosis, arterial occlusion with renal loss, and arterial rupture with extravasations and pseudo aneurysm formation and may require surgical intervention.
There are presently no specific studies or reports on the long-term prognosis and outcome of FMD in children . The pathophysiology, management and long-term outcomes of FMD in children are drastically in need of attention and increased research effort.
The vascular sub type of Ehlers-Danlos Syndrome (type IV) has been associated with medial FMD. This syndrome should be suspected in patients with multiple aneurysms and/or tears (dissections) in arteries in addition to the typical angiographic findings of FMD. There have been isolated reports of FMD associated with other disorders, including Alport’s Syndrome, pheochromocytoma, Marfan’s Syndrome, Moyamoya disease, and Takayasu's arteritis .
- Poloskey, S., Olin, J., Mace, P., & Gronik, H. (2012). Fibromuscular dysplasia 125. American Heart Association. pp. 636–639. doi:10.1161/CIRCULATIONAHA.111.090449.
- Olin J.W., Froehlich J., Gu X., et al. (2012). The United States registry for fibromuscular dysplasia: results in the first 447 patients 125. pp. 3182–90. doi:10.1161/CIRCULATIONAHA.112.091223.
- Olin, J. W. (2007). Recognizing And Managing Fibromuscular Dysplasia. 74(4). Cleveland Clinic Journal of Medicine. pp. 273–274.
- Olin, J. W., & Sealove, B. A (2011). Diagnosis, management, and future developments of fibromuscular dysplasia 53. Journal of Vascular Surgery. pp. 826–836. doi:10.1016/j.jvs.2010.10.066.
5. Hendricks N, Baheti A, Angle JF, Sabri SS, Saad WE, Cutlip D, Matsumoto AH. Is Fibromuscular dysplasia (FMD underdiagnosed? A comparison of the prevalence of FMD seen in patients enrolled into the CORAL trial versus a single institution population of renal donor candidates. J Vasc Int Radiol 2013;24(suppl);S17.
6. Sos TA, Pickering TG, Sniderman K, et al. Percutaneous transluminal renal angioplasty in renovascular hypertension due to atheroma or Fibromuscular dysplasia. N Engl J Med. 1983;309;274-279
7. Baert AL, Wilms G, Amery A, Vermylen J, Suy R. Percutaneous transluminal renal angioplasty: initial results and long-term follow-up in 202 patients. Cardiovasc Int Radiol. 1990;13;22-28
8. Tegtmeyer CJ, Selby JB, Hartweel GD, Ayers C, Tegtmeyer V. Results and complications of angioplasty in Fibromuscular disease. Circulation. 1991;83(suppl);I-155-I-161.
9. Luscher TF, Lie JT, Stanson AW, Houser OW, Hollier LH, Sheps SG. Arterial Fibromuscular dysplasia. Mayo Clin Proc. 1987;62;931-952.
10. Mettiger KL, Ericson K. Fibromuscular dysplasia and the brain – observations on angiographic, clinical and genetic characteristics. Stroke. 1982;13;46-52.
11. Schievink WI. Spontaneous dissection of the carotid and vertebral arteries. N Engl J Med. 2001;344;898-906.
12. Kirton, A., Crone, M., Benseler, S., Mineyko, A., Armstrong, D., Wade, A., & Crous-Tsanaclis, A. M. (2013). Fibromuscular dysplasia and childhood stroke. Brain, 136, 1846–1856 doi: 10.1093/brain/awt111 13. Mace, P., "FMDSA Fibromuscular Dysplasia Society of America." Welcome to FMDSA. N.p., 2011. Web. 22 July 2013.
14. Meyers, K. E., & Sharma, N. (2007). Fibromuscular dysplasia in children and adolescents. Cath Lab Digest, 15(6).
15. Tullus, K. (2013). Renovascular hypertension—is it fibromuscular dysplasia or Takayasu arteritis. Pediatric Nephrology, 28(2), 191-196.